Evidence map›Paper›PMID 39511424›Full record

ArticleScientific reports2024

Metabolic profiling unveils enhanced antibacterial synergy of polymyxin B and teixobactin against multi-drug resistant Acinetobacter baumannii.

Maytham Hussein, Zhisen Kang, Stephanie L Neville, Rafah Allobawi, Varsha Thrombare, Augustine Jing Jie Koh, Jonathan Wilksch, Simon Crawford, Mudher Khudhur Mohammed, Christopher A McDevitt and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maytham HusseinMonash Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, VIC, 3800, Australia. maytham.hussein.old@monash.edu.
Zhisen KangMonash Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, VIC, 3800, Australia.
Stephanie L NevilleDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC, 3010, Australia.
Rafah AllobawiMonash Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, VIC, 3800, Australia.
Varsha ThrombareMonash Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, VIC, 3800, Australia.
Augustine Jing Jie KohMonash Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, VIC, 3800, Australia.
Jonathan WilkschDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC, 3010, Australia.
Simon CrawfordMonash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, VIC, 3800, Australia.
Mudher Khudhur MohammedDepartment of Pharmacy, Al-Manara college for medical sciences, Maysan, Iraq.
Christopher A McDevittDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC, 3010, Australia.
Mark BakerDiscipline of Biological Sciences, Priority Research Centre in Reproductive Biology, Faculty of Science and IT, University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia.
Gauri G RaoTitus Family, Department of Clinical Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA, 90089-9121, USA. gaurirao@usc.edu.
Jian LiMonash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, VIC, 3800, Australia. jian.li@monash.edu.
Tony VelkovMonash Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, VIC, 3800, Australia. tony.velkov@monash.edu.

Funding

Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant ‘superbugs’R01AI170889 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MALONEY, SARA ELIZABETH, RAO, GAURI G · 2022 to 2025
$3.8M
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approachR01AI146241 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RAO, GAURI G, VELKOV, TONY · 2019 to 2023
$3.0M
The National Institute of Allergy and Infectious Diseases R01AI146241The National Institute of Allergy and Infectious Diseases R01AI170889
6 · The paper itself

Abstract

This untargeted metabolomics study investigated the synergistic antibacterial activity of polymyxin B and Leu

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsDepsipeptidesDrug Resistance, Multiple, BacterialDrug SynergismMetabolomicsMicrobial Sensitivity TestsPolymyxin BMetabolomeAnti-Bacterial AgentsDepsipeptidesPolymyxin BteixobactinA. baumanniiAntimicrobial resistanceMetabolomicsPolymyxin BTeixobactin

Identifiers

PMID39511424
PMCPMC11543821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.